Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I
Journal article published in 2016 by
Kosh Agarwal 
,
Emily O. Dumas,
Giovanni B. Gaeta,
Sam Lee,
Adrian Streinu-Cercel,
Eckart Schott,
Raul J. Andrade,
Alma M. Perez,
Jacob George,
Igor G. Bakulin,
Rui T. Marinho,
Resat Ozaras,
Mariem Charafeddine,
Li Liu,
Tami Pilot-Matias
and other authors.
,
Emily O. Dumas,
Giovanni B. Gaeta,
Sam Lee,
Adrian Streinu-Cercel,
Eckart Schott,
Raul J. Andrade,
Alma M. Perez,
Jacob George,
Igor G. Bakulin,
Rui T. Marinho,
Resat Ozaras,
Mariem Charafeddine,
Li Liu,
Tami Pilot-Matias
and other authors.
